AILANI[™] version 3.1 Release Notes (RC)

Artificial Intelligence LANguage Interface

Table of Contents

Version Information AILANI version 3.1	3
Supported client platforms and operating systems	3
Main Features	4
Next generation search for Key Opinion Leaders (KOL) New Refiners Updated Social Graph Visualization	4 4
Search within the Social Graph Viewer More Entry Points allow visualizing the Social Graph	
Clinical Trials Search	6
Food Product Search	7
Additional Export Options	7
Answers are ranked by relevance	7
Redirect from Chemical Report to all patents referencing chemical structure of interest	7
Other Changes	9
Chemistry Chemistry Editor Chemical Search Algorithms	9
User Interface/User Experience	9
Concept selectors below sunburst refiner ranked by number of hits	
User Preferences Dialog allows List Size Customization	
Updated Typography and Imagery	
Displaying Maps within Lists of Organizations	
Redesigned Organization Reports Search Field User Query Parsing	
Knowledge Graph Updates	14
Linked Data	14
Patent Data	14
Food Products	14
Chemistry Data	14
Geographical Information	14
Ontologies	15

A LabVantage Company	AILANI™ for Life Sciences Version 3.1			
Release Notes – Rev. 1.0 RC	Code: AILANI-LS	AILANI version 3.1		
Revision History				
About AILANI				
About LabVantage – Biomax				

Version Information AILANI version 3.1

These release notes are current as of April 2023.

AILANI version 3.1 is a full public release.

AILANI is based on the BioXM Semantic Core platform version 264.7.

Supported client platforms and operating systems

The AILANI semantic search platform version 3.1 is a zero-footprint Web application. No additional software is required beyond one of the supported Web Browsers.

Supported Web Browsers are:

- Microsoft Edge 84, or later
- Google Chrome 84, or later
- Apple Safari Version 14 or higher

Support for Mozilla Firefox has been deprecated and will be removed April 1st, 2023.

Note that usage of a Chromium/Blink-based Browser (Chrome, Edge) or a WebKit-based Browser (Safari) is recommended. The JavaScript Performance of Mozilla Firefox significantly lags behind those browsers, resulting in an inferior user experience.

Note that usage of the Microsoft Edge compatibility mode with Internet Explorer 11 (IE Mode) is not supported. In addition, Legacy Edge mode emulating the EdgeHTML engine instead of Chromium is also not supported.

Supported Operating Systems are:

- Microsoft Windows 11 (recommended)
- Microsoft Windows 10
- Apple macOS 13 Ventura (recommended)
- Apple macOS 12 Monterey
- Apple macOS 11 Big Sur

Note that usage on small mobile devices (mobile phones) is not yet fully supported.

Main Features

Next generation search for Key Opinion Leaders (KOL)

Currently one can search across 15 million world-wide experts based on ORCID IDs. These authors are part of a big author network consisting of 73 million co-author relationships. To identify experts or knowledgeable people in your field of research you enter a disease, a drug, a technology, an organism or any other relevant term in the main search box.

Within the KOL Tab Panel an author-centric result list is returned. The list can be further refined for additional expertise, number of publications, publication activity or type.

New Refiners

New refiners associated with the employment of authors have been introduced (Figure 1), such as


- Countries (associated with the affiliation ORCID user enter when filling in or updating their records at <u>orcid.org</u>)
- Most recent Country (Country associated with the most recent affiliation in orcid.org)
- Most recent Role (Most recent Employment ORCID user filed in <u>orcid.org</u>)
- Start Year (associated with the Employment entry in orcid.org)

🕥 📙 🌑 🔍 My Tags	•~ 🐥		DEVELOPMENT v3	よ s 🔩 🏤 🖪 💡
Keyword Results 91,921	Inswers 🔍 📩	KOL 3		
ind your expert			Per page: 50 ¢ Results: 3	Personal Details
7 Expert	~	Select	ed Items: 0 📕 Add or Remove Bookmarks 🗣 Add Tags 🗸 Show/Hide 🗸 Sorted by Score 🗸 📳 Export Selection V - 🖧 Social Graph	Mitsutoshi Tominaga ORCID ID: 0000-0002-1254-1803 [2] # of Publications: 60
Self-assigned Keywords	~		O Mitsutoshi Tominaga	eMail: tominaga@juntendo.ac.jp WebSites: Juntendo.ltch Research
forks			Expertise: 짧 Adult 짧 Animals ໝ Anti-Inflammatory Agents 짧 Antibodies, Monoclonal 쩛 Apoptosis 限 Bacteroidetes 照 Betacellulin 限 Biological	Center (JIRC) (https://www.juntendo.ac.jp/g raduate/laboratory/labo/kank
Publication Type	~		Assay 强 Biomarkers G Cell Differentiation 옆 Cell Movement 쭾 Cell Shape 쭾 Cells, Cultured 꿮 Chemotaxis 쭯 Cyanobacteria 陞 Cytokines ® Read more	yo_igaku/jirc/en/index.html) Keywords: Itch
Publication Activity	~		Number of 60 Publications:	Neuroscience Dermatology
Number of Publications	~		Source: Open Researcher and Contributor ID (ORCID)	Publications © Effects of 308 nm excimer light treatment on the skin microbiome of atopic dermatitis
mployment				patients. Kurosaki, Y., et al. "Effects of 308 Nm Excimer
[®] Countries	~		💿 Kazufumi Kunimura	Light Treatment on the Skin Microbiome of Atopic Dermatitis Patients." <i>Photodermatology</i> ,
Most recent Country	Ŷ		Expertise: 펼 Anima Acid Sequence ඕ Animala 臆 Binding Sites 뤏 cholesterol Esters ඕ Demaitlis, Atopic 聲 Drug Development 竳 Guanine Nucleotide Exchange Factors 隆 Humans 옆 Immunomodulation 절 Immunotherapy	Photoimmunology & Photomedicine, vol. 36, no. 3, May 2020, pp. 185–191, doi:10.1111/phpp.12531. 31880842 [2]
Most recent Role	~		32 Intereukins 쨆 Models, Molecular 쨉 Neoplasms 短 Oxysterols 蹬 PDZ @ Read more Number of 12	Robust induction of neural crest cells to derive peripheral sensory neurons from human induced pluripotent stem cells.
Associate Professor (2)			Publications: Source: Open Researcher and Contributor ID (ORCID)	Umehara, Y., et al. "Robust Induction of Neural Crest Cells to Derive Peripheral Sensory
Assistant Professor (1)	Apply		•	Neurons from Human Induced Pluripotent Stem Cells." Scientific Reports, vol. 10, no. 1, Mar. 2020, p. 4360, doi:10.1038/s41598-020-60036-
			© Takanori Kanazawa	z. <u>32152328</u>
E Start Year	\sim		Expertise: 짧 Animals 쬁 Dermatitis, Atopic 쬁 Drug Delivery Systems 쨅 Epidermis 평 Liouid Crystals 평 Mice, Inbred ICR, 행 Olicopentides, 행	Molecular and Cellular Mechanisms of Itch in Psoriasis.

Figure 1: KOL result page with "Employment refiners"

Updated Social Graph Visualization

A refined set of authors can be selected (Figure 2) and visualized by an optimized Social Graph. The social graph calculates and visualizes a network of authors that connects the selected ones finding the shortest paths between them.



🏐 📕 🌑 🖤 Му Та	igs 🗸 💧 🖕		> DEVELOPMENT v3	📩 2 🍡 🍙 🖽 🕐
Keyword Results 119,840	Answers 3	KOL 38		
Find your expert			Per page: 50 ¢ Results: 38	Personal Details
🚓 Expertise	~	✓ Selecte	l items: 38	Cenanual Maverakis ORCID ID: 0000-0002-6294-6294 [2] # of Publications: 80
Self-assigned Keywords Search within refiner Pooriasis (38) Dermatology (10) Atopic Dermatitis (5) Cinical Trials (4) Melanoma (4)	~ • Q		Semanual Maverakis Expertise: A Acquermatitis S Action Potentials R Adaptor Protein Complex 3 S Adjostity R Administration, Urtaneous R Administration, Intranseal R Adolescent R Adolescent R Adaptor Protein Administration, Intranseal R Adjostity R Administration, Intranseal R Read more. Number of 80 Publications: Source: Open Researcher and Contributor ID (ORCID)	WebSites: Blogger (http://www.maverakis.com/) Twitter (http://www.maverakis.com/) Linkedin (https://www.linkedin.com//in/n averakis) Google Plus (https://glus.google.com/1083) 3379619700007089) Mendeley (https://www.mendeley.com/pr office/emanu-maverakis)
€ Works	Apply		Susana Armesto Expertise: ত Acrylates ত Adalimumab o Adiposity o Adolescent o Age Distribution o Agents of Onset o Agents of Anti-Informatory Agents, Non-Steroldad o Agents of Anti-Informatory Agents, Non-Steroldad o Agents of Anti-Informatory Agents, Non-Steroldad o Antibudies, Antineutrophil Cytoplasmic o Arginine o Arthritis, Psoriatic o Back o Beach ore	Academia (https://ucdavis.academia.edu/ EmanualMaverakis) About me (https://about.me/maverakis) Redati (https://www.redat.com/user/ Maverakis.ab/)
			Publications: Source: Open Researcher and Contributor ID (ORCID)	Instagram (https://www.instagram.com/e

Figure 2: Selection of refined authors for Social Graph

Search within the Social Graph Viewer

Authors can now be searched for within the network using the search box on top of the network (Figure 3)





Figure 3: Search for authors in Social Graph

Authors highlighted in yellow are "bookmarked" authors, the size of the author node is proportional to the number of authored publications. The thickness of the edges is proportional to the number of co-authored publications.

More Entry Points allow visualizing the Social Graph

The Social Graph can also be accessed from the Author Report within the 3rd panel in the two Tabs "Coauthors" and "Similar Authors" (Figure 4)






Figure 4: Access to the Social Graph from the Author Report

Clinical Trials Search

Within the specialized search for Clinical Trials accessible via the Quick Link buttons below the main search box two additional refiners have been introduced:

- Actual Enrollment
- Anticipated Enrollment

🕥 📙 📎 🗣 My Tags 🗸	.		Clinical Trials	💄 2 🍡 🏠 🗓 😗
(psoriasis	٩		(1 of 152) Per page: 50 (*) Results: 7,561 (*) none Roolmarks (*) Add Tase (*) Stow Adds (*) Sort by (*)	Details : Large Plaque Psoriasis
Aggregate and Filter Clinical Trials		Selected items: 0 H Add or Ren		Psoriasis is a chronic, debilitating skin disorder with an estimated prevalence of 2%. Psoriatic skin lesions start with initial pinhead-sized macules and then coalesce into plaques of varying sizes. Despite the great strides in the studies for psoriatis, it is still unclear why psoriatic skin lesions start with small macules and then soread
💑 Chemical, Drug or Biologic	~	an estimated prevalen		peripherally.
₩≟ Sponsor	~		soriasis an 01, 2014 00:00:00 3	To study peripheral spreading of psoriasis, investigators plan to study small plaque psoriasis in comparison to large plaque psoriasis in the Korean population. Large
₩2 Status	~		ompleted linicalTrials.gov	plaque psoriasis is the most common form of psoriasis, seen in approximately 90% of all psoriasis participants. Large psoriatic plaques are >5 cm in size and localize to
TE Country	~	•••		the extensor aspects of the elbows, knees, scalp, and genital area. On the other hand, small plaque psoriasis is the common or typical form of psoriasis that occurs
to Clinical Trials	~		Tildrakizumab on Epigenetic Age iidrakizumab reverses peripheral blood leukocyte DNA methylation (epigenetic aging)	particularly in Korea and other Asian countries. Korean small plaque psoriasis, even when chronic, remains <2 cm in size and is widely distributed on the upper trunk and proximal extremities.
E Actual Enrollment	^	A	soriasis soriasis ging gingenetic Disorder	Investigators hypothesize that the expression of immune- related genes are different between small and large plaque psoriasis. The study of a genetically homogeneous cohort. characterized by the relatively high prevalence of
0-50 (2038) 51-150 (965) 151-1000 (840)		Start Date: A) Anticipated 30 Enrollment:		small plaque psoriasis in the Korean population, may filter out spurious signals while allowing for significant associations to emerge from a relatively low number of participants.
□ 1001-10000 (118) □ >10000 (9)	Apply		leruting InicalTrials.gov	By comparing small and large plaque psoriasis, it is expected this study could lead to new understandings of the mechanisms involved in spreading of psoriatic plaques and provide new insights into psoriasis development.
Anticipated Enrollment	~	🗆 📕 🍙 Oral Psoria	sis Treatment Adherence and Intervention Study	Study Type: Interventional Country: United States Status: Completed

Figure 5: New Enrollment refiner for Clinical Trials search

A LabVantage Company	AILANI [™] for Life Sciences Version 3	.1
Release Notes – Rev. 1.0 RC	Code: AILANI-LS	AILANI version 3.1

Food Product Search

Note that the Food Product Search is only available for subscribers of the "Food, Nutrition & Health" Persona.

• Additional Refiners for aggregation and filtering of food nutrition facts have been added (Figure 6).




Figure 6: Refiners for Nutrition Facts

Additional Export Options

- Export for Authors in KOL Search
- Export for Rare Diseases in Rare Disease Search

Answers are ranked by relevance

Answers are ranked automatically by relevance based on journal impact factor and up-to-dateness. Answers derived from publications with a high impact factor and published most recently are ranked higher.

Redirect from Chemical Report to all patents referencing chemical structure of

interest

Within Chemical reports cross referenced databases including patents are listed in the left panel in the section "Sources" (Figure 7). If a chemical structure of interest is mentioned within a patent the respective link with the InChI Key and a patent icon can be used to be redirected to a report listing all additional patents mentioning the chemical structure of interest as well as patents mentioning similar structures to the chemical structure of interest (Figure 8)

A LabVantage Company	AILANI™ for Life Sciences Version 3.1	
Release Notes – Rev. 1.0 RC	Code: AILANI-LS	AILANI version 3.1

folecular Structu	ire :	Compound Information	:
Description: A benzoate ester r guanidinobenzoic hydroxyphenyl)ace	constant example for the formal condensation of the carboxy group of 4 active with the hydroxy group of 24 dimethylaminoly 2-acustrill (L4 active with the hydroxy group of 24 dimethylaminoly 2-acustrill (L4 active with the hydroxy group of 24 dimethylaminoly 2-acustrill (L4 active with the hydroxy group of 24 dimethylaminoly 2-acustrill (L4 b) of a mergine and its currently under investigation for its Simal molecule 3 0 2315 Campanda 4	B Burmary A; Lineage ↓ Similar ① Citations ○ DOR ② Assays ② Dong Targets ▲₀ Dong Pr Calculated Chemical Properties Molecular wright: 394.13 Mole ramatic: 394.13 Formal charge: ○ Isg P: 0.058 Rule of there: ○ Chemical Broogenetics Commical Broogenetics Date of there: ○ Descriptors Commical Broogenetics Mole: molecular Code/2040/561-34(2)17(23)1-28-16(20)11-18-3-16(10-6-13)29-19(27)1-68-715(8-14)23-2020 Mole: molecular Code/2040/561-34(2)17(23)1-28-16(20)11-18-3-16(10-6-13)29-19(27)1-68-715(8-14)23-2020 Mole: molecular Code/2040/561-34(2)17(23)1-28-16(20)11-18-3-16(10-6-13)29-19(27)1-68-715(8-14)23-2020 Mole: Molecular Code/2040/561-34(2)17(23)1-28-16(20)11-18-3-16(10-6-13)29-19(27)1-68-715(8-14)23-2020 Mole: molecular Code/2040/561-34(2)17(23)1-28-16(20)1-18-3-16(10-6-13)29-19(27)1-68-715(8-14)23-2020 Mole: molecular Code/2040/561-34(2)17(23)1-28-16(20)1-18-3-16(10-6-13)29-19(27)1-68-715(8-14)23-2020 Mole: molecular Code/2040/561-34(2)17(23)1-28-16(20)1-18-3-16(10-6-13)29-19(27)1-68-715(8-14)23-2020 Mole: molecular Code/2040/561-34(2)17(23)1-28-16(20)1-10-16(20)-20-10-10-10-10-10-10-10-10-10-10	
	Carnostat [INN] Read more		
ATC: Contributing Sources:	(i) BE2AB0 camostat ∰ carnostat @ 4-(2: (dimethylamino) 2 oxoethyl) 2 oxoethylphenyl 4- guandinobencosta(CamostatUS9199927, camostat @ canostat @ canostat @ cANOSTAT		
Source: Patents with this Structure:			

Figure 7: Chemical report of Camostat with cross reference to additional USPTO patents

Molecular Structure of I	interest	Abstract			
Camostat	Щ	di Patents R	efferencing Canadat (2) (2) Patenta Referencing Similars (2) Per page (2) (2) (2) (2) (2) (2) (2) (2) (2) (2)	OVERDOSE A Inventors: The invention prov	MPOSITIONS RESISTANT TO IND ABUSE Thomas E. JENKINS; Half Moon Bay, CA US @ Read more Idde pharmaceutical compositions comprising astorimetratinal enzyme-table opicioprofising astoric
carboxy group of 4-guani (dimethylamino)-2-oxoeth inhibitor of the human tra and its mesylate salt is o effectiveness in COVID-1	outed of from the formal condensation of the diroberrois and with the hydroxy group of 2- hydroykowycherolatents. It is a potent namembrane processe centre 2 (TMPRSS2) comenty under twinestigation for its		Comparing a constraining enzyme-cleavable ampletamine prodrugs and inhibitors thereof Comparing a constraining enzyme-cleavable ampletamine prodrugs and inhibitors thereof Comparing a constraining enzyme-cleavable ampletamine prodrugs and inhibitors Comparing a constraining enzyme-cleavable ampletamine prodrugs andinters Comparing a constraining enzyme-cleavable ampletamine	gastrointestinal er minimally absorbe pharmacokinetic p ingestion. An opti	Aug 22, 2017
Black Bac no Wimings: PuRChem: C 22 Synoryms: Cam Straction () () () () () () () () () () () () ()	ottat 1:3/97 2:3/97 2:3/10 2:3/8/96 2:3/96 2:3/96 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3:3/97 3		COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF Methods Bendemain Be		
source: roipo	sinory or Monecular Sindcoures		thereof Referenced 3_Carrostat Structures: 3_J.LAINISCH.GAVRWARTFUORISK.N		

Figure 8: Chemical Report listing all patents mentioning structure of interest (Camostat)

A LabVantage Company	AILANI [™] for Life Sciences Version 3	.1
Release Notes – Rev. 1.0 RC	Code: AILANI-LS	AILANI version 3.1

Other Changes

Chemistry

Chemistry Editor

The Chemistry Editor "Chem Composer" from Kekule.js (Figure 9) has been updated to the latest release version 1.0.

Kekule.js is an open source cheminformatics toolkit that provides a 2D diagram editor for molecules and other chemical objects (License: <u>MIT</u>; DOI: <u>10.1021/acs.jcim.6b00167</u>).




Figure 9: Kekule.js Chem Composer chemistry editor


Chemical Search Algorithms

- The chemical search algorithms are now more robust in case one or multiple chemical structures that are similar have stereo-chemical (3D) information attached.
- The chemical search algorithms now work reliably with ionic compounds as query structures.

User Interface/User Experience

Concept selectors below sunburst refiner ranked by number of hits

Concepts displayed below the sunburst control are now ranked by the frequency of concepts identified within documents. The number of hits across all documents is displayed after the concept name.






Figure 10: Concepts ranked by occurrence below sunburst control

User Preferences Dialog allows List Size Customization

The user preferences dialog (Figure 11) has been extended to allow changing the default list size for all list views. In addition to the default list size of 25 items, list sizes of 10, 50 or 100 items are supported.

Note, that increasing the list size may slow down the loading time of result lists.

	e system settings to customize AILANI. For exam ge the language, and more.	ple, you can select to show or hide a b	ookmarks bar,	choose your	preferred
olor Scheme:	Default (Biomax)		*		
how Main Toolba	🔿 No 💽 Yes				
how QuickAccess	Advanced Search × Draw Structure > Drugs × Targets × Ontologist ×	Clinical Trials	×		
how Announcem n Home Page1:	is and Comments O No 🔿 Yes				
anguage: E	ish (EN)		Ŧ		
efault Number of	ows: 🔵 10 🗿 25 🔵 50 🔵 100				
Warning Increasing the	mber of default rows for a result list can slow dow	wn the loading time.			
	collaboration features are available only for AILAN				

Figure 11: Extended User Preferences Dialog

A LabVantage Company	AILANI [™] for Life Sciences Version 3	.1
Release Notes – Rev. 1.0 RC	Code: AILANI-LS	AILANI version 3.1

Updated Typography and Imagery

The AILANI Portal now uses Font Awesome Pro 6, introducing new symbols and images.



Displaying Maps within Lists of Organizations

Lists within AILANI of research organizations have been updated to show a zoomed-in map of the location (Figure 12).





Figure 12: Lists of Research Organizations with Map

Redesigned Organization Reports

The Organization Reports have been redesigned (Figure 13), now providing information about the organization structure (parent and child organizations, related organizations), known current and previous staff, and a large map (Figure 14) providing an overview of the organization of interest and all its child organizations.






Figure 13: Redesigned Organization Report




Figure 14: Overview Map of Organization and its Children

A LabVantage Company	AILANI [™] for Life Sciences Version 3.1	
Release Notes – Rev. 1.0 RC	Code: AILANI-LS	AILANI version 3.1

Search Field User Query Parsing

The query parser that interprets user search requests (Figure 15) is now more forgiving of unintentional user input. For example, multiple spaces between words previously prevented successful matching of concepts, resulting in a pure keyword search as a fallback.

i	inflammatory bowel disease
Inflam	matory Bowel Disease
inflam	matory bowel disease protein 1
inflam	matory bowel disease protein 1 (human)

Figure 15: Main Search Field



Knowledge Graph Updates

Linked Data

Patent Data

• Patents (USPTO): The number of patents (public domain information, source: <u>United States Patent</u> and <u>Trademark Office</u>) maintained by AILANI increased to 12.8 million. Note: Only 3 million are currently accessible in AILANI. The full set will be available with the next release.

Food Products

• Open Food Facts (OFF): <u>Open Food Facts</u> data (License: <u>ODbL</u>) increased from 2.4 to 2.8 million food products, updated to a current snapshot (March 2023).

Chemistry Data

Molecular Structures: The central repository of molecular structures has been updated to a total number of 7.2 million unique chemical structures.

The repository is built and updated on a regular schedule (weekly to monthly, specific to the source) based on the following resources:

- ChEMBL <u>ChEMBL</u> is a manually curated database of bioactive molecules with drug-like properties. It brings together chemical, bioactivity and genomic data to aid the translation of genomic information into effective new drugs. (License: CC BY-SA 3.0; DOI: 10.1093/nar/gky1075)
- ChEBI <u>Chemical Entities of Biological Interest</u> are molecular entities focused on 'small' chemical compounds, referring to any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer, etc. (License: <u>CC BY 4.0</u>; DOI: <u>10.1093/nar/gkv1031</u>)
- DSSTox The U.S. EPA <u>Distributed Structure-Searchable Toxicity</u> (DSSTox) Database provides a highquality public chemistry resource for supporting improved predictive toxicology. (License: <u>CC0 1.0</u>; DOI: <u>10.1016/j.comtox.2019.100096</u>)
- SwissLipids <u>SwissLipids</u> is an expert curated resource that provides a framework for the integration of lipid and lipidomic data with biological knowledge and models. (License: <u>CC BY 4.0</u>; DOI: <u>10.1093/bioinformatics/btv285</u>)
- GtoPdb Ligands The IUPHAR/BPS Guide to PHARMACOLOGY is an expert-curated resource of ligand-activity-target relationships, the majority of which come from high-quality pharmacological and medicinal chemistry literature. (License: <u>CC BY-SA 4.0</u>; DOI: <u>10.1093/nar/gkab1010</u>)
- UNII The Unique Ingredient Identifier is linked to a substance's molecular structure or descriptive information and is generated by the <u>Global Substance Registration System</u> (GSRS) of the FDA.
- USPTO Compounds in Chemical Patents in United States Patent and Trademark Office (USPTO)

PubChem — Open chemistry database at the NIH (License: Public domain; DOI: 10.1093/nar/gkac956)

• FDA Drug Labels — Prescription drug/biological products

Geographical Information

• **Geolocations:** Based on the <u>GeoNames</u> database (License: <u>CC BY 4.0</u>), the number of geolocations has been updated to 13 million worldwide geolocations covering Cities, Villages, Buildings, Farms, Mountains, Forests, Lakes, Parks, etc.

A LabVantage Company	AILANI™ for Life Sciences Version 3.1	
Release Notes – Rev. 1.0 RC	Code: AILANI-LS	AILANI version 3.1

Ontologies

Primary Ontologies

No changes have been introduced to the primary domain ontologies. Larger updates are planned for the next release of AILANI (Summer 2023):

- Open Biomedical Master Ontology (OBMO) (© LabVantage Biomax GmbH)
- Open Food and Nutrition Master Ontology (OFMO) (© LabVantage Biomax GmbH)

Secondary Ontologies

- Research Organization Registry Ontology (ROR): A Biomax-generated ontology based on the content of the <u>Research Organization Registry</u> (License: <u>CCO 1.0</u>) has been updated to its latest version (March 2023), increasing the number of supported research organizations to 105 thousand organizations.
- Chemical Entities of Biological Interest (ChEBI): The <u>ChEBI ontology</u> (License: <u>CC BY 4.0</u>) has been updated to the official release version 218.

A LabVantage Company	AILANI [™] for Life Sciences Version 3.1	
Release Notes – Rev. 1.0 RC	Code: AILANI-LS	AILANI version 3.1

Revision History

Version	Date	Comment	Author
1.0	March 30 th 2023	Release Candidate	Angela Bauch

A LabVantage Company	AILANI [™] for Life Sciences Version 3.1	
Release Notes – Rev. 1.0 RC	Code: AILANI-LS	AILANI version 3.1

About AILANI

AILANI is a state-of-the-art semantic search and discovery platform designed to revolutionize information access and knowledge management in the life sciences and pharmaceutical sectors. Powered by advanced AI, natural language processing, and knowledge graph technology, AILANI enables users to quickly uncover relevant insights, promote interdisciplinary collaboration, and drive innovation. With its intuitive interface, AILANI supports organized serendipity by connecting disparate data sources and fostering the discovery of hidden relationships, helping researchers make informed decisions and accelerate the development of groundbreaking solutions in their respective fields.

About LabVantage – Biomax

LabVantage - Biomax is a leading provider of cutting-edge solutions designed to empower organizations in the life sciences and pharmaceutical industries. Combining LabVantage's expertise in laboratory informatics with Biomax's deep understanding of semantic technology and knowledge management, LabVantage - Biomax offers a comprehensive suite of innovative solutions, including the AILANI semantic search and discovery platform. By leveraging advanced technologies like AI, natural language processing, and semantic search, LabVantage - Biomax enables organizations to accelerate R&D, streamline workflows, and foster innovation by harnessing the power of organized serendipity through interconnected data and insights.

Publication date March 2023 Copyright © 2022-2023 LabVantage — Biomax GmbH

Biomax and AlLANI are registered trademarks of LabVantage — Biomax GmbH in Germany and other countries. Microsoft and Windows are registered trademarks of Microsoft Corporation. Apple, macOS, iPad and Safari are registered trademarks of Apple Inc. Firefox and Mozilla are registered trademarks of The Mozilla Foundation Registered names, trademarks, etc., used in this document, even when not specifically marked as such, are not to be considered unprotected by law.